Advertisement

Chemotherapy of Advanced Gastric Carcinoma in Elderly and High-Risk Patients

  • P. Preusser
  • H. Wilke
  • W. Achterrath
  • U. Fink
Conference paper

Abstract

Gastric carcinoma is the second leading cause of death in cases of malignant neoplasias in the Federal Republic of Germany. A total of 28 of 100,000 inhabitants die from gastric carcinoma every year.1

Keywords

Gastric Cancer Clin Oncol Gastric Carcinoma Advanced Gastric Cancer Cytostatic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Statistisches Bundesamt Wiesbaden: Gesundheitswesen, Fachserie 12 Todesursachen 1983. Statistisches Bundesamt. Wiesbaden, W. Kohlhammer, Stuttgart, 1984, p 12.Google Scholar
  2. 2.
    Waterhouse JAH: Epidemiology of gastric cancer, in Preece PE, Cuschieri A, Wellwood JM (eds): Cancer of the Stomach. London, Grune & Stratton, 1985, p 1.Google Scholar
  3. 3.
    Hunter CP, Frelick RW, Feldman AR, et al: Selection factors in clinical trials: results from the community clinical oncology program physician’s patient log. Cancer Treat Rep 1987; 71: 559.PubMedGoogle Scholar
  4. 4.
    Lee YJ, Catane R, Rozencweig M, et al: Analysis and interpretation of response rates for anticancer drugs. Cancer Treat Rep 1970; 63: 1713.Google Scholar
  5. 5.
    Walder S, Green M, Muggia F: The role of anthracyclines in the treatment of gastric cancer. Cancer Treat Rev 1985; 12: 105.CrossRefGoogle Scholar
  6. 6.
    Queisser W, Flechtner H: Chemotherapy of advanced gastric carcinoma. Onkologie 1986; 9: 319.PubMedCrossRefGoogle Scholar
  7. 7.
    DeSimone PA, Gams R, Birch R: Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a Southwestern Cancer Study Group trial. Cancer Treat Rep 1986; 70: 1043.PubMedGoogle Scholar
  8. 8.
    Louie AC, Issell BF: Amsacrine (AMSA) - a clinical review. J Clin Oncol 1985; 3: 562.PubMedGoogle Scholar
  9. 9.
    Aisner J, Van Echo DA, Whitacre J, et al: A phase I trial of continuous infusion VP16–213 (Etoposide). Cancer Chemother Pharmacol 1982; 7: 157.PubMedGoogle Scholar
  10. 10.
    Greco FA, Johnson DH, Hande RK, et al: High-dose etoposide (VP-16) in small-cell lung cancer. Sem Oncol 1985; 12 (suppl 2): 42.Google Scholar
  11. 11.
    Kelsen DP, Magill G, Cheng E, et al: Phase II trial of etoposide (VP16) in the treatment of upper gastrointestinal malignancies, abstract. Proc ASCO 1982;96:C-371.Google Scholar
  12. 12.
    Seeber S, Osieka R, Schmidt CG, et al: In vivo resistance towards anthracyclines, etoposide, and cis-diaminedichloroplatinum (II). Cancer Res 1982; 67: 4719.Google Scholar
  13. 13.
    Tozak LK, Von Hoff DD: The cardiotoxicity of anticancer agents, in Perry MC, Yabro JW (eds): Toxicity of Chemotherapy. Orlando, Grune & Stratton, 1984, p 199.Google Scholar
  14. 14.
    Franke H: Wesen and Bedeutung der Polypathie and Multimorbidität in der Alterscheilkunde. Internist 1984; 25: 451.PubMedGoogle Scholar
  15. 15.
    Lipschitz DA: Conference: cancer in the elderly: basic science and clinical aspects. Ann Intern Med 1985; 102: 218.PubMedGoogle Scholar
  16. 16.
    Vestal RE: Drug use in the elderly: a review of problems and special considerations. Drugs 1978; 16: 358.PubMedCrossRefGoogle Scholar
  17. 17.
    Gallmeier WM: Krebstherapie im Alter. Mun Med Wochens 1977; 43: 1379.Google Scholar
  18. 18.
    Douglass HO, Trave F, Milliron S, et al: A phase II trial of 5-fluorouracil and high-dose intravenous leukovorin in gastric carcinoma. J Clin Oncol 1987; 5: 1150.PubMedGoogle Scholar
  19. 19.
    Machover D, Goldschmidt E, Chollet P: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986; 4: 685.PubMedGoogle Scholar
  20. 20.
    Hill BT: Potential of continuous tumor cell lines for establishing patterns of cross-resistance and collateral sensitivity in vitro. Drugs Exp Clin Res 1986; 12: 293.PubMedGoogle Scholar
  21. 21.
    Osswald H, Kunz W: Therapeutic synergism of etoposide and fluorouracil combined sequentially in advanced leukemia L1210, abstract. Cancer Res Clin Oncol 1987; 113(suppl): 53; 39.Google Scholar
  22. 22.
    World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. World Health Organization, 1979, p 1.Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 1989

Authors and Affiliations

  • P. Preusser
  • H. Wilke
  • W. Achterrath
  • U. Fink

There are no affiliations available

Personalised recommendations